GLP-1 Drugs: A Paradigm Shift in Cardiovascular Medicine
Review argues GLP-1 drugs represent a paradigm shift in cardiovascular medicine, moving from diabetes drugs to essential cardiovascular protective therapies.
Quick Facts
What This Study Found
Review argues GLP-1 drugs represent a paradigm shift in cardiovascular medicine, moving from diabetes drugs to essential cardiovascular protective therapies.
Key Numbers
GLP-1 RAs approved for T2D and obesity. Evidence reviewed for CVD, MASLD/MASH, CKD, and neurological conditions.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide evidence.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Evidence comparison?
- ?Next steps?
Trust & Context
- Key Stat:
- Key finding Review argues GLP-1 drugs represent a paradigm shift in cardiovascular medicine, moving from diabete
- Evidence Grade:
- Based on design.
- Study Age:
- Published in 2025.
- Original Title:
- GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?
- Published In:
- Pharmacology & therapeutics, 269, 108824 (2025)
- Authors:
- Arredouani, Abdelilah
- Database ID:
- RPEP-09987
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What does this mean?
Review argues GLP-1 drugs represent a paradigm shift in cardiovascular medicine, moving from diabetes drugs to essential cardiovascular protective therapies.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09987APA
Arredouani, Abdelilah. (2025). GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?. Pharmacology & therapeutics, 269, 108824. https://doi.org/10.1016/j.pharmthera.2025.108824
MLA
Arredouani, Abdelilah. "GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?." Pharmacology & therapeutics, 2025. https://doi.org/10.1016/j.pharmthera.2025.108824
RethinkPeptides
RethinkPeptides Research Database. "GLP-1 receptor agonists, are we witnessing the emergence of ..." RPEP-09987. Retrieved from https://rethinkpeptides.com/research/arredouani-2025-glp1-receptor-agonists-are
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.